Evidence Library

Showing 10 of 80 results.
Staff •
Center for Public Health Law Research

This dataset, which is published to the Prescription Drug Abuse Policy System (PDAPS.org) is longitudinal and displays key features of state commercial insurance and Medicaid coverage laws related to medication for opioid use disorder (MOUD) across all 50 states and the District of Columbia, in effect between August 1, 2017 and August 1, 2020.

 
Staff •
Center for Public Health Law Research

This dataset, which is published to the Prescription Drug Abuse Policy System (PDAPS.org), is cross-sectional and displays key features of licensing requirements related to medications for opioid use disorder (MOUD) treatment for facilities and providers across all 50 states and the District of Columbia in effect as of August 1, 2020. 

 
Nicolas P Terry, LLM •
Indiana University Robert H. McKinney School of Law

Medicaid is at the core of the opioid overdose epidemic. Both state and federal government reactions continue to shape the outcomes of this epidemic while death rates in some states continue to increase. There is a strong correlation between those suffering from opioid use disorder and those eligible for Medicaid. Most significantly, individuals with opioid use disorder enrolled in their state’s Medicaid program experience greater positive health outcomes compared to those without coverage.

 

Medication-Assisted Treatment (MAT) uses medications, such as Methadone, in conjunction with behavioral therapy and counseling to treat opioid addiction. MAT with methadone is required to be distributed to individuals through an Opioid Treatment Program (OTP). MAT with methadone for opioid addiction is subject to federal law, with specific requirements such as physician evaluations, toxicology testing, counseling, and treatment planning. Some states go beyond what is required by the federal law and place stricter restrictions on OTPs, while other states simply defer to the federal law.

 

According to the 2014 National Survey on Drug Use and Health (NSDUH), 10 million people aged 12 or older reported driving under the influence of illicit drugs. As more states have legalized medical and recreational marijuana and with the high prevalence of prescription drug use in the United States, drugged driving has become a public health issue. In response, states have passed laws intended to decrease traffic accidents and deaths related to drugged driving. 

 

Prescription drug monitoring programs (PDMPs) collect patient-specific prescription information in centralized databases in an effort to reduce the misuse of controlled medicines. This dataset captures laws governing PDMP reporting and authorized use. The topic includes who is required to report to the PDMP, what drug schedules must be reported to the PDMP, and whether the PDMP is authorized to share data with insurers, state Medicaid programs, or PDMPs located in other states.

This is a longitudinal dataset, displaying laws from January 1, 1998 to July 1, 2016.

 

Prescription drug monitoring programs (PDMPs) collect patient-specific prescription information in centralized databases in an effort to reduce the misuse of controlled substances. This dataset captures the important dates for each state’s PDMP, including the dates of enactment, operation, and user access. These dates were compiled through contact with PDMP administrators from each state program by Brandeis’ PDMP Training and Technical Assistance Center (TTAC). The information is publicly available and is published here in dataset format with the permission of Brandeis’ PDMP TTAC.

 

Prescription drug monitoring programs (PDMPs) collect patient-specific prescription information in centralized databases in an effort to reduce the misuse of controlled medicines. This dataset captures rules governing the administration of state PDMPs, including which department collects and stores the data, how the PDMP program is funded, and program's powers and duties to act under the law.

This is a longitudinal dataset, displaying laws from January 1, 1998 to July 1, 2016.

This dataset was created by Legal Science.

 

Prescription drug monitoring programs (PDMPs) collect patient-specific prescription information in centralized databases in an effort to reduce the misuse of controlled medicines. This dataset encompasses laws regulating which professions have access to the database and for what purpose, whether practitioners can delegate their access, whether patients can see their own information, and the extent to which access to individually-identified records may be granted for law enforcement purposes.

This is a longitudinal dataset, displaying laws from January 1, 1998 to July 1, 2016.

 

Pages